Stock Track | Glaukos Surges 5% as Q1 Earnings Beat Expectations, Revenue Jumps 25%

Stock Track

May 03, 2025

Shares of Glaukos (NYSE: GKOS) are soaring 5.04% in intraday trading on Friday, as the medical device company reported better-than-expected first-quarter 2025 results. The strong performance, highlighted by significant revenue growth and a narrower net loss, has boosted investor confidence in the company's prospects.

Glaukos announced Q1 2025 revenue of $106.7 million, marking a robust 25% increase from the same period last year and surpassing analyst estimates by 3.8%. The company's net loss narrowed substantially to $18.1 million, or $0.32 per share, compared to a loss of $0.82 per share in Q1 2024. This represents a 56% improvement in net loss and beat earnings per share (EPS) expectations by 21%.

Looking ahead, analysts forecast Glaukos' revenue to grow at an average rate of 20% per annum over the next three years, outpacing the projected 8% growth for the US Medical Equipment industry. This positive outlook, combined with the company's strong Q1 performance, appears to be driving today's stock surge despite a 12% decline over the past week.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106231879"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106231879\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106231879?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-03 00:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106231879","market":"us","top_or_hot":-1,"title":"Stock Track | Glaukos Surges 5% as Q1 Earnings Beat Expectations, Revenue Jumps 25%","media":"Stock Track","content":"<p>Shares of Glaukos (NYSE: GKOS) are soaring 5.04% in intraday trading on Friday, as the medical device company reported better-than-expected first-quarter 2025 results. The strong performance, highlighted by significant revenue growth and a narrower net loss, has boosted investor confidence in the company's prospects.</p>\n\n<p>Glaukos announced Q1 2025 revenue of $106.7 million, marking a robust 25% increase from the same period last year and surpassing analyst estimates by 3.8%. The company's net loss narrowed substantially to $18.1 million, or $0.32 per share, compared to a loss of $0.82 per share in Q1 2024. This represents a 56% improvement in net loss and beat earnings per share (EPS) expectations by 21%.</p>\n\n<p>Looking ahead, analysts forecast Glaukos' revenue to grow at an average rate of 20% per annum over the next three years, outpacing the projected 8% growth for the US Medical Equipment industry. This positive outlook, combined with the company's strong Q1 performance, appears to be driving today's stock surge despite a 12% decline over the past week.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Glaukos Surges 5% as Q1 Earnings Beat Expectations, Revenue Jumps 25%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Glaukos Surges 5% as Q1 Earnings Beat Expectations, Revenue Jumps 25%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-03 00:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Glaukos (NYSE: GKOS) are soaring 5.04% in intraday trading on Friday, as the medical device company reported better-than-expected first-quarter 2025 results. The strong performance, highlighted by significant revenue growth and a narrower net loss, has boosted investor confidence in the company's prospects.</p>\n\n<p>Glaukos announced Q1 2025 revenue of $106.7 million, marking a robust 25% increase from the same period last year and surpassing analyst estimates by 3.8%. The company's net loss narrowed substantially to $18.1 million, or $0.32 per share, compared to a loss of $0.82 per share in Q1 2024. This represents a 56% improvement in net loss and beat earnings per share (EPS) expectations by 21%.</p>\n\n<p>Looking ahead, analysts forecast Glaukos' revenue to grow at an average rate of 20% per annum over the next three years, outpacing the projected 8% growth for the US Medical Equipment industry. This positive outlook, combined with the company's strong Q1 performance, appears to be driving today's stock surge despite a 12% decline over the past week.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GKOS","symbol_name":"Glaukos Corp","start_time":0,"source_url":"","article_id":"1106231879","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106231879","pubTimestamp":1746204290,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Glaukos  are soaring 5.04% in intraday trading on Friday, as the medical device company reported better-than-expected first-quarter 2025 results. The strong performance, highlighted by significant revenue growth and a narrower net loss, has boosted investor confidence in the company's prospects.Glaukos announced Q1 2025 revenue of $106.7 million, marking a robust 25% increase from the same period last year and surpassing analyst estimates by 3.8%. The company's net loss narrowed substa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GKOS":"Glaukos Corp"},"translate_title":"股票赛道Glaukos飙升5%，第一季度盈利超出预期，收入增长25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"Shares of Glaukos (NYSE: GKOS) are soaring 5.04% in intraday trading on Friday, as the medical device company reported better-than-expected first-quarter 2025 results. The strong performance, highlighted by significant revenue growth and a narrower net loss, has boosted investor confidence in the company's prospects.\nGlaukos announced Q1 2025 revenue of $106.7 million, marking a robust 25% increase from the same period last year and surpassing analyst estimates by 3.8%. The company's net loss narrowed substantially to $18.1 million, or $0.32 per share, compared to a loss of $0.82 per share in Q1 2024. This represents a 56% improvement in net loss and beat earnings per share (EPS) expectations by 21%.\nLooking ahead, analysts forecast Glaukos' revenue to grow at an average rate of 20% per annum over the next three years, outpacing the projected 8% growth for the US Medical Equipment industry. This positive outlook, combined with the company's strong Q1 performance, appears to be driving today's stock surge despite a 12% decline over the past week.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}